These emerging therapies , Tirzepatide , represent a groundbreaking advancement in addressing type 2 diabetes and possibly other disorders. They all are classified as GLP-1 pathway activators , meaning they to emulate the endogenous GLP-1 hormone , boosting metabolic production and reducing hunger . Despite Semaglutide each operates largely similar